Correlation of IDH1 mutation with clinicopathologic factors and prognosis in primary glioblastoma: A report of 118 patients from China

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Yan, Wei ^a   Zhang, Wei ^a   You, Gan ^a   Bao, Zhaoshi ^a   Wang, Yongzhi ^a   Liu, Yanwei ^a   Kang, Chunsheng ^c   You, Yongping ^b   Wang, Lei ^a   Jiang, Tao ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c Tianjin Neurological Institute   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; KI 67 ANTIGEN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN P53; TEMOZOLOMIDE; TUMOR MARKER; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; BRAIN SURGERY; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CHINESE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION REGULATION; GENE MUTATION; GENETIC ASSOCIATION; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IDH1 GENE; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; MUTATIONAL ANALYSIS; ONCOGENE; OUTCOME ASSESSMENT; PREOPERATIVE EVALUATION; PRIMARY TUMOR; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN METHYLATION; PYROSEQUENCING; WILD TYPE; ASIAN; BRAIN TUMOR; CHINA; COHORT ANALYSIS; ETHNOLOGY; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; MORTALITY; MUTATION; PHYSIOLOGY; PROGNOSIS; RISK FACTOR; SURVIVAL;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; BRAIN NEOPLASMS; CHINA; COHORT STUDIES; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GLIOBLASTOMA; HUMANS; ISOCITRATE DEHYDROGENASE; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 84856098344     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030339     Document Type: Article

References (26)

1. Quick A, Patel D, Hadziahmetovic M, Chakravarti A, Mehta M, (2010) Current therapeutic paradigms in glioblastoma. Rev Recent Clin Trials 5: 14-27.
2. Yan W, Zhang W, Jiang T, (2011) Oncogene addiction in gliomas: implications for molecular targeted therapy. J Exp Clin Cancer Res 30: 58.
3. Weller M, Felsberg J, Hartmann C, Berger H, Steinbach JP, et al. (2009) Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol 27: 5743-5750.
4. Weller M, Stupp R, Reifenberger G, Brandes AA, van den Bent MJ, et al. (2010) MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol 6: 39-51.
5. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, et al. (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360: 765-773.
6. von Deimling A, Korshunov A, Hartmann C, (2011) The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations. Brain Pathol 21: 74-87.
7. Christensen BC, Smith AA, Zheng S, Koestler DC, Houseman EA, et al. (2011) DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma. J Natl Cancer Inst 103: 143-153.
8. Houillier C, Wang X, Kaloshi G, Mokhtari K, Guillevin R, et al. (2010) IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 75: 1560-1566.
9. Scherer HJ, (1940) Cerebral astrocytomas and their derivatives. Am J Cancer 40: 159-198.
10. Zhang W, Qiu XG, Chen BS, Li SW, Cui Y, et al. (2009) Antiangiogenic therapy with bevacizumab in recurrent malignant gliomas: analysis of the response and core pathway aberrations. Chin Med J (Engl) 122: 1250-1254.
11. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, et al. (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321: 1807-1812.
12. Ichimura K, Pearson DM, Kocialkowski S, Bäcklund LM, Chan R, et al. (2009) IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol 11: 341-347.
13. Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, et al. (2009) Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27: 4150-4154.
14. Kanu OO, Mehta A, Di C, Lin N, Bortoff K, et al. (2009) Glioblastoma multiforme: a review of therapeutic targets. Expert Opin Ther Targets 13: 701-718.
15. Herbst RS, (2004) Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 59: 21-26.
16. Ciardiello F, Tortora G, (2008) EGFR antagonists in cancer treatment. N Engl J Med 358: 1160-1174.
17. Katzenberger T, Petzoldt C, Höller S, Mäder U, Kalla J, et al. (2006) The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma. Blood 3407.
18. Burcombe R, Wilson GD, Dowsett M, Khan I, Richman PI, et al. (2006) Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer. Breast Cancer Res 8: R31.
19. Labussiere M, Sanson M, Idbaih A, Delattre JY, (2010) IDH1 Gene Mutations: A New Paradigm in Glioma Prognosis and Therapy? The Oncologist 15: 196-199.
20. Wang W, Rastinejad F, El-Deiry WS, (2003) Restoring p53-dependent tumor suppression. Cancer Biol Ther 2: S55-63.
21. Muller PA, Caswell PT, Doyle B, Iwanicki MP, Tan EH, et al. (2009) Mutant p53 drives invasion by promoting integrin recycling. Cell 139: 1327-1341.
22. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, et al. (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352: 997-1003.
23. Fukushima T, Takeshima H, Kataoka H, (2009) Anti-glioma therapy with temozolomide and status of the DNA-repair gene MGMT. Anticancer Res 29: 4845-4854.
24. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, et al. (2010) Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17: 510-522.
25. van den Bent MJ, Dubbink HJ, Marie Y, Brandes AA, Taphoorn MJ, et al. (2010) IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res 16: 1597-1604.
26. Jin Q, Zhang W, Qiu XG, Yan W, You G, et al. (2011) Gene expression profiling reveals Ki-67 associated proliferation signature in human glioblastoma. Chin Med J (Engl) 17: 2584-2588.